Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

205.12 +6.60 (+3.33%)
Streaming Delayed Price Updated: 3:36 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable. 
Via The Motley Fool
News headline image
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗
The company has also crushed broader equities over the past five years. 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a... 
Via Benzinga
News headline image
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a... 
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock. 
Via Benzinga
News headline image
Axsome Therapeutics Q2 Earnings Call Highlights ↗
Axsome Therapeutics (NASDAQ:AXSM) reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for... 
Via MarketBeat
Topics Earnings
News headline image
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗
These innovative biotech companies should reap the benefits of their breakthroughs. 
Via The Motley Fool
News headline image
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Sometimes, little-known stocks are worth buying. 
Via The Motley Fool
News headline image
Better Growth Buy: Axsome vs Revolution Medicines ↗
These stocks both scored a win in the first half of the year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗
These stocks have jumped in the double- and triple-digits. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. ↗
The stock has soared more than 220% in three years. 
Via The Motley Fool
News headline image
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline ↗
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive... 
Via MarketBeat
News headline image
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch ↗
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive... 
Via MarketBeat
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
The old healthcare model is breaking down. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Recognizes Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article